Indication
In combination with pembrolizumab for the first‑line treatment of advanced renal cell carcinoma in adults
Medicine details
- Medicine name:
- lenvatinib (Kisplyx)
- SMC ID:
- SMC2476
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 13 June 2022